{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T16:12:20Z","timestamp":1772554340135,"version":"3.50.1"},"reference-count":76,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T00:00:00Z","timestamp":1747267200000},"content-version":"vor","delay-in-days":15,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Although the relative proportion of triple-negative breast cancer decreases with age, its prevalence is rising with an aging population. This study examined real-world treatment practices, whether age in older women with triple-negative breast cancer affects therapy and outcomes, focusing on the potentially curable nature of early-stage triple-negative breast cancer.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A Preferred Reporting Items for Systematic Reviews and Meta-Analyses, PRISMA\u2013compliant search using population, intervention, comparison, outcomes criteria identified literature from 2014 to 2023 across 5 databases (MEDLINE, Embase, PubMed, Web of Science, and Scopus), focusing on women aged 65 years and older with early-stage triple-negative breast cancer.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>From 7171 records, 37 studies were included. Older women with triple-negative breast cancer exhibited less aggressive features, including lower Ki67, higher androgen receptor, and higher Bcl2 expression. Breast-conserving surgery with radiation therapy (RT) was associated with improved overall survival and breast cancer\u2013specific survival, with fewer recurrences compared with mastectomy with or without RT. Older women with triple-negative breast cancer were more likely to receive RT than systemic therapy, and the lack of RT correlated with worse outcomes. Multivariate analyses showed that systemic treatment improved 5-year overall survival and breast cancer\u2013specific survival. Overall, outcomes did not show significant differences between women aged 70 years and older and women younger than 70 years at a median follow-up of 46\u2009months.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The lack of overall outcome improvements for older women with triple-negative breast cancer following treatment may not solely be due to absent targetable receptors because the intrinsic biology in older patients may be relatively favorable. Instead, treatment selection biases against active treatment due to age-related factors may contribute substantially. Treatment decisions should be biology based and guided by a multidisciplinary, holistic, and patient-centered approach that carefully considers comorbidities, functional status, social support, and patient preferences.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jncics\/pkaf049","type":"journal-article","created":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T22:55:04Z","timestamp":1747349704000},"source":"Crossref","is-referenced-by-count":1,"title":["Treatment strategies for triple-negative primary breast cancer in older women: a systematic review"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-4351-9510","authenticated-orcid":false,"given":"Buraq","family":"Ahmed","sequence":"first","affiliation":[{"name":"Medical School, University of Cambridge , Cambridge,","place":["United Kingdom"]},{"name":"Breast Surgery, Cambridge University Hospitals , Cambridge,","place":["United Kingdom"]}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1165-008X","authenticated-orcid":false,"given":"Qutaiba","family":"Al-Khames Aga","sequence":"additional","affiliation":[{"name":"School of Pharmacy, University of Waterloo , Waterloo,","place":["Canada"]}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2973-0755","authenticated-orcid":false,"given":"Kwok-Leung","family":"Cheung","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Nottingham , Derby,","place":["United Kingdom"]}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9518-0902","authenticated-orcid":false,"given":"Jana","family":"de Boniface","sequence":"additional","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden, and Department of Surgery, Capio St G\u00f6ran\u2019s Hospital , Stockholm,","place":["Sweden"]}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1002-2118","authenticated-orcid":false,"given":"Michael","family":"Gnant","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Center, Medical University of Vienna , Vienna,","place":["Austria"]},{"name":"Austrian Breast & Colorectal Cancer Study Group , Vienna,","place":["Austria"]}]},{"given":"Maria-Joao","family":"Cardoso","sequence":"additional","affiliation":[{"name":"Breast Unit, Champalimaud Foundation and Lisbon University Faculty of Medicine , Lisbon,","place":["Portugal"]}]},{"given":"Emad","family":"Rakha","sequence":"additional","affiliation":[{"name":"Pathology Department, University of Nottingham, and Nottingham University Hospitals NHS Trust , Nottingham,","place":["United Kingdom"]}]},{"given":"Thiraviyam","family":"Elumalai","sequence":"additional","affiliation":[{"name":"Breast Oncology, Cambridge University Hospitals , Cambridge,","place":["United Kingdom"]}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9744-7372","authenticated-orcid":false,"given":"Nadia","family":"Harbeck","sequence":"additional","affiliation":[{"name":"Breast Center, Department of OB&GYN and CCCMunich, LMU University Hospital , Munich,","place":["Germany"]}]},{"given":"Orit","family":"Kaidar-Person","sequence":"additional","affiliation":[{"name":"Breast Radiation Unit, Sheba Tel Hashomer , Ramat Gan,","place":["Israel"]},{"name":"School of Medicine, Faculty of Medical & Health Sciences, Tel Aviv University , Tel Aviv,","place":["Israel"]}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3144-0493","authenticated-orcid":false,"given":"Amit","family":"Agrawal","sequence":"additional","affiliation":[{"name":"Medical School, University of Cambridge , Cambridge,","place":["United Kingdom"]},{"name":"Breast Surgery, Cambridge University Hospitals , Cambridge,","place":["United Kingdom"]}]}],"member":"286","published-online":{"date-parts":[[2025,5,15]]},"reference":[{"key":"2025062612014381200_pkaf049-B1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.21037\/abs-21-89","article-title":"Breast cancer in the older population: A global challenge\u2014an epidemiological perspective","volume":"7","author":"Lemij","year":"2023","journal-title":"Ann Breast Surg"},{"key":"2025062612014381200_pkaf049-B2","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1056\/NEJMra1001389","article-title":"Triple-negative breast cancer","volume":"363","author":"Foulkes","year":"2010","journal-title":"N Engl J Med"},{"key":"2025062612014381200_pkaf049-B3","doi-asserted-by":"publisher","first-page":"R55","DOI":"10.1186\/bcr3156","article-title":"Occurrence of breast cancer subtypes in adolescent and young adult women","volume":"14","author":"Keegan","year":"2012","journal-title":"Breast Cancer Res"},{"key":"2025062612014381200_pkaf049-B4","doi-asserted-by":"publisher","first-page":"856268","DOI":"10.3389\/fendo.2022.856268","article-title":"Prognostic factors and models for elderly (\u226570 years old) primary operable triple-negative breast cancer: analysis from the National Cancer Database","volume":"13","author":"Tang","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2025062612014381200_pkaf049-B5","doi-asserted-by":"publisher","first-page":"e258","DOI":"10.1016\/j.clbc.2024.01.016","article-title":"Prognosis and adjusting factors in elderly patients with triple-negative breast cancer: comparing with young and middle age groups","volume":"24","author":"You","year":"2024","journal-title":"Clin Breast Cancer"},{"key":"2025062612014381200_pkaf049-B6","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1001\/jama.295.21.2492","article-title":"Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study","volume":"295","author":"Carey","year":"2006","journal-title":"JAMA"},{"key":"2025062612014381200_pkaf049-B7","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","article-title":"Triple-negative breast cancer: clinical features and patterns of recurrence","volume":"13","author":"Dent","year":"2007","journal-title":"Clin Cancer Res"},{"key":"2025062612014381200_pkaf049-B8","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1001\/jamaoncol.2017.0001","article-title":"Brain metastases in newly diagnosed breast cancer","volume":"3","author":"Martin","year":"2017","journal-title":"JAMA Oncol"},{"key":"2025062612014381200_pkaf049-B9","doi-asserted-by":"publisher","first-page":"e669","DOI":"10.1016\/j.clbc.2019.05.011","article-title":"T1-2N0M0 triple-negative breast cancer treated with breast-conserving therapy has better survival compared to mastectomy: a SEER\u00a0population-based retrospective analysis","volume":"19","author":"Li","year":"2019","journal-title":"Clin Breast Cancer"},{"key":"2025062612014381200_pkaf049-B10","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.surg.2022.05.026","article-title":"Age disparities in triple-negative breast cancer treatment and outcomes: an NCDB analysis","volume":"172","author":"Drapalik","year":"2022","journal-title":"Surgery"},{"key":"2025062612014381200_pkaf049-B11"},{"key":"2025062612014381200_pkaf049-B12","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"},{"key":"2025062612014381200_pkaf049-B13","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/j.annonc.2021.06.023","article-title":"Customizing local and systemic therapies for women with early breast cancer: The St Gallen International Consensus Guidelines for treatment of early breast cancer 2021","volume":"32","author":"Burstein","year":"2021","journal-title":"Ann Oncol"},{"key":"2025062612014381200_pkaf049-B14","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1200\/JCO.21.01506","article-title":"CALGB 40603 (Alliance): long-term outcomes and genomic correlates of response and survival after neoadjuvant chemotherapy with or without carboplatin and bevacizumab in triple-negative breast cancer","volume":"40","author":"Shepherd","year":"2022","journal-title":"J Clin Oncol"},{"key":"2025062612014381200_pkaf049-B15","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S1470-2045(14)70160-3","article-title":"Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial","volume":"15","author":"von Minckwitz","year":"2014","journal-title":"Lancet Oncol"},{"key":"2025062612014381200_pkaf049-B16","doi-asserted-by":"publisher","first-page":"S1257","DOI":"10.1016\/j.annonc.2023.10.008","article-title":"LBA18 pembrolizumab or placebo plus chemotherapy followed by pembrolizumab or placebo for early-stage TNBC: updated EFS results from the phase III KEYNOTE-522 study","volume":"34","author":"Schmid","year":"2023","journal-title":"Ann Oncol"},{"key":"2025062612014381200_pkaf049-B17","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.14694\/EdBook_AM.2015.35.e31","article-title":"Triple-negative breast cancer: molecular subtypes and new targets for therapy","author":"Lehmann","year":"2015","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2025062612014381200_pkaf049-B18","doi-asserted-by":"publisher","first-page":"e12611","DOI":"10.1200\/JCO.2023.41.16_suppl.e12611","article-title":"Neoadjuvant PARP inhibitors in patients with early HER2-negative breast cancer harboring BRCA 1\/2 germline mutations: a systematic review and meta-analysis","volume":"41","author":"Dacoregio","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025062612014381200_pkaf049-B19","first-page":"58","article-title":"Management of triple-negative breast cancer in older patients: how is it different?","volume":"32","author":"Ss S","year":"2018","journal-title":"Oncology (Williston Park)"},{"key":"2025062612014381200_pkaf049-B20","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.3390\/curroncol28040215","article-title":"Cancer-specific outcomes in the elderly with triple-negative breast cancer: a systematic review","volume":"28","author":"Yoon","year":"2021","journal-title":"Curr Oncol"},{"key":"2025062612014381200_pkaf049-B21","author":"National Audit of Breast Cancer in Older Patients (NABCOP)","year":"2020"},{"key":"2025062612014381200_pkaf049-B22"},{"key":"2025062612014381200_pkaf049-B23","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1056\/NEJM199912303412706","article-title":"Underrepresentation of patients 65 years of age or older in cancer-treatment trials","volume":"341","author":"Hutchins","year":"1999","journal-title":"N Engl J Med"},{"key":"2025062612014381200_pkaf049-B24","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2025062612014381200_pkaf049-B25","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"2025062612014381200_pkaf049-B26","doi-asserted-by":"publisher","first-page":"953","DOI":"10.2217\/cer-2021-0273","article-title":"Breast-conserving surgery versus mastectomy for older women with triple-negative breast cancer: population-based study","volume":"11","author":"Mburu","year":"2022","journal-title":"J Comp Eff Res"},{"key":"2025062612014381200_pkaf049-B27","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.breast.2022.02.006","article-title":"Is breast conservation superior to mastectomy in early stage triple negative breast cancer?","volume":"62","author":"Saifi","year":"2022","journal-title":"Breast"},{"key":"2025062612014381200_pkaf049-B28","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s10549-020-05686-3","article-title":"Breast-conserving surgery without axillary lymph node surgery or radiotherapy is safe for HER2-positive and triple negative breast cancer patients over 70 years of age","volume":"182","author":"Zhong","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"2025062612014381200_pkaf049-B29","doi-asserted-by":"publisher","first-page":"4707","DOI":"10.1007\/s12325-022-02279-y","article-title":"Can radiotherapy after breast-conserving surgery be omitted in elderly patients with early-stage, hormone-receptor negative breast cancer? A population-based study and proposed nomogram","volume":"39","author":"Xu","year":"2022","journal-title":"Adv Ther"},{"key":"2025062612014381200_pkaf049-B30","doi-asserted-by":"publisher","first-page":"e2021881","DOI":"10.1001\/jamanetworkopen.2020.21881","article-title":"Evaluation of adjuvant treatments for T1 N0 M0 triple-negative breast cancer","volume":"3","author":"Zhai","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2025062612014381200_pkaf049-B31","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1111\/tbj.13443","article-title":"Omission of radiation therapy following breast conservation in older (\u226570 years) women with T1-2N0 triple-negative breast cancer","volume":"25","author":"Haque","year":"2019","journal-title":"Breast J"},{"key":"2025062612014381200_pkaf049-B32","first-page":"1611","article-title":"Addition of chemotherapy to local therapy in women aged 70 years or older with triple-negative breast cancer: a propensity-matched analysis","volume-title":"Lancet Oncol","author":"Pezzi","year":"2020"},{"key":"2025062612014381200_pkaf049-B33","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1002\/ijc.29617","article-title":"Prognostic role of adjuvant radiotherapy in triple-negative breast cancer: a historical cohort study","volume":"137","author":"Bhoo-Pathy","year":"2015","journal-title":"Int J Cancer"},{"key":"2025062612014381200_pkaf049-B34","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.radonc.2022.05.006","article-title":"The association of internal mammary and medial supraclavicular lymph node radiation technique with clinical outcomes: results from the EORTC 22922\/10925 randomised trial","volume":"172","author":"Kaidar-Person","year":"2022","journal-title":"Radiother Oncol"},{"key":"2025062612014381200_pkaf049-B35","doi-asserted-by":"publisher","first-page":"e079089","DOI":"10.1136\/bmj-2023-079089","article-title":"Randomised controlled trials on radiation dose fractionation in breast cancer: systematic review and meta-analysis with emphasis on side effects and cosmesis","volume":"386","author":"Lee","year":"2024","journal-title":"BMJ"},{"key":"2025062612014381200_pkaf049-B36","doi-asserted-by":"publisher","first-page":"e99","DOI":"10.1016\/j.clbc.2016.05.011","article-title":"Radiotherapy in patients 70 years and older with triple-negative breast cancer","volume":"16","author":"Algan","year":"2016","journal-title":"Clin Breast Cancer"},{"key":"2025062612014381200_pkaf049-B37","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.breast.2017.06.011","article-title":"Radiation therapy utilization and outcomes for older women with breast cancer: impact of molecular subtype and tumor grade","volume":"35","author":"Haque","year":"2017","journal-title":"Breast"},{"key":"2025062612014381200_pkaf049-B38","doi-asserted-by":"publisher","first-page":"e117","DOI":"10.1016\/S2666-7568(20)30018-0","article-title":"Adjuvant chemotherapy and survival in women aged 70 years and older with triple-negative breast cancer: a\u00a0Swedish population-based propensity score-matched analysis","volume":"1","author":"Janeva","year":"2020","journal-title":"Lancet Healthy Longev"},{"key":"2025062612014381200_pkaf049-B39","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s10549-022-06751-9","article-title":"Neoadjuvant systemic therapy in geriatric breast cancer patients: a\u00a0National Cancer Database (NCDB) analysis","volume":"196","author":"Brown","year":"2022","journal-title":"Breast Cancer Res Treat"},{"key":"2025062612014381200_pkaf049-B40","doi-asserted-by":"publisher","first-page":"502","DOI":"10.17305\/bjbms.2022.8163","article-title":"Effectiveness of adjuvant chemotherapy for elderly patients with triple-negative breast cancer","volume":"23","author":"Guo","year":"2023","journal-title":"Biomol Biomed"},{"key":"2025062612014381200_pkaf049-B41","doi-asserted-by":"publisher","first-page":"113426","DOI":"10.1016\/j.ejca.2023.113426","article-title":"Major cardiovascular adverse events in older adults with early-stage triple-negative breast cancer treated with adjuvant taxane + anthracycline versus taxane-based chemotherapy regimens: a SEER-Medicare study","volume":"196","author":"Roy","year":"2024","journal-title":"Eur J Cancer"},{"key":"2025062612014381200_pkaf049-B42","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ejca.2023.02.014","article-title":"Clinical outcomes of adjuvant taxane plus anthracycline versus taxane-based chemotherapy regimens in older adults with node-positive, triple-negative breast cancer: a SEER\u2013Medicare study","volume":"185","author":"Roy","year":"2023","journal-title":"Eur J Cancer"},{"key":"2025062612014381200_pkaf049-B43","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s10549-021-06424-z","article-title":"Evaluating anthracycline + taxane versus taxane-based chemotherapy in older women with node-negative triple-negative breast cancer: a\u00a0SEER-Medicare study","volume":"191","author":"Schreiber","year":"2022","journal-title":"Breast Cancer Res Treat"},{"key":"2025062612014381200_pkaf049-B44","doi-asserted-by":"publisher","first-page":"e719","DOI":"10.1016\/j.wneu.2019.04.247","article-title":"Primary central nervous system tumors: comparing two national cancer registries","volume":"128","author":"Yolcu","year":"2019","journal-title":"World Neurosurg"},{"key":"2025062612014381200_pkaf049-B45","doi-asserted-by":"publisher","first-page":"867583","DOI":"10.3389\/fonc.2022.867583","article-title":"Chemotherapy decision-making and survival outcomes in older women with early triple-negative breast cancer: evidence from real-world practice","volume":"12","author":"Xiu","year":"2022","journal-title":"Front Oncol"},{"key":"2025062612014381200_pkaf049-B46","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.jgo.2020.09.004","article-title":"Treatment patterns, risk for hospitalization and mortality in older patients with triple negative breast cancer","volume":"12","author":"Valachis","year":"2021","journal-title":"J Geriatr Oncol"},{"key":"2025062612014381200_pkaf049-B47","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1200\/JCO.2023.41.16_suppl.510","article-title":"Prognosis and trends in chemotherapy use for patients with stage IA triple-negative breast cancer (TNBC): a population-based study","volume":"41","author":"Tarantino","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025062612014381200_pkaf049-B48","doi-asserted-by":"publisher","first-page":"867583","DOI":"10.3389\/fonc.2022.867583","article-title":"Chemotherapy decision-making and survival outcomes in older women with early triple-negative breast cancer: evidence from real-world practice","volume":"12","author":"Xiu","year":"2022","journal-title":"Front Oncol"},{"key":"2025062612014381200_pkaf049-B49","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1111\/tbj.12813","article-title":"Triple-negative breast cancer in the elderly: prognosis and treatment","volume":"23","author":"Kaplan","year":"2017","journal-title":"Breast J"},{"key":"2025062612014381200_pkaf049-B50","first-page":"1276","article-title":"Excellent clinical outcome of triple-negative breast cancer in younger and older women","volume":"20","author":"Bulut","year":"2015","journal-title":"J Buon"},{"key":"2025062612014381200_pkaf049-B51","doi-asserted-by":"publisher","first-page":"e0128345","DOI":"10.1371\/journal.pone.0128345","article-title":"Age-related disparity in immediate prognosis of patients with triple-negative breast cancer: a population-based study from SEER cancer registries","volume":"10","author":"Zhu","year":"2015","journal-title":"PLoS One"},{"key":"2025062612014381200_pkaf049-B52","doi-asserted-by":"publisher","first-page":"16","DOI":"10.21037\/abs-23-58","article-title":"Octogenarians with triple negative breast cancer","volume":"8","author":"Spoer","year":"2024","journal-title":"Ann Breast Surg"},{"key":"2025062612014381200_pkaf049-B53","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1111\/ecc.12346","article-title":"Clinicopathological features and prognosis of triple-negative breast cancer: a\u00a0comparison between younger (&lt;60) and elderly (\u226560) patients","volume":"25","author":"Qiu","year":"2016","journal-title":"Eur J Cancer Care"},{"key":"2025062612014381200_pkaf049-B54","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/tbj.13251","article-title":"Adjuvant treatment and survival in older women with triple negative breast cancer: a\u00a0Surveillance, Epidemiology, and End Results analysis","volume":"25","author":"Kozak","year":"2019","journal-title":"Breast J"},{"key":"2025062612014381200_pkaf049-B55","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s10549-020-05727-x","article-title":"A comparison between young and old patients with triple-negative breast cancer: biology, survival and metastatic patterns","volume":"182","author":"Tzikas","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"2025062612014381200_pkaf049-B56","doi-asserted-by":"publisher","first-page":"S0","DOI":"10.4103\/jcrt.jcrt_90_21","article-title":"Influence of advanced age on the prognosis of triple-negative breast cancer patients: a\u00a0Surveillance, Epidemiology, and End Results-based study","volume":"19","author":"Tan","year":"2023","journal-title":"J Cancer Res Ther"},{"key":"2025062612014381200_pkaf049-B57","doi-asserted-by":"publisher","first-page":"e100573","DOI":"10.1371\/journal.pone.0100573","article-title":"Biological characteristics and clinical outcome of triple negative primary breast cancer in older women\u2014comparison with their younger counterparts","volume":"9","author":"Syed","year":"2014","journal-title":"PLoS One"},{"key":"2025062612014381200_pkaf049-B58","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.humpath.2021.01.005","article-title":"Clinicopathological characteristics and prognostic marker of triple-negative breast cancer in older women","volume":"111","author":"Honma","year":"2021","journal-title":"Hum Pathol"},{"key":"2025062612014381200_pkaf049-B59","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41523-023-00508-3","article-title":"Immunotherapy in breast cancer: an overview of current strategies and perspectives","volume":"9","author":"Debien","year":"2023","journal-title":"NPJ Breast Cancer"},{"key":"2025062612014381200_pkaf049-B60","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.surg.2022.05.026","article-title":"Age disparities in triple-negative breast cancer treatment and outcomes: an NCDB analysis","volume":"172","author":"Drapalik","year":"2022","journal-title":"Surgery (United States)"},{"key":"2025062612014381200_pkaf049-B61","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1007\/s10549-011-1891-6","article-title":"Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype","volume":"133","author":"Lowery","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"2025062612014381200_pkaf049-B62","doi-asserted-by":"publisher","first-page":"e257","DOI":"10.1016\/j.ejso.2023.03.156","article-title":"Surgical outcomes of breast conserving surgery performed under local versus general anaesthesia","volume":"49","author":"Ghosh","year":"2023","journal-title":"Eur J Surg Oncol"},{"key":"2025062612014381200_pkaf049-B63","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s00238-022-02009-1","article-title":"Oncoplastic breast surgery in elderly primary breast cancer: time to serve more surgically?","volume":"46","author":"Garreffa","year":"2022","journal-title":"Eur J Plast Surg"},{"key":"2025062612014381200_pkaf049-B64","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1093\/bjs\/znad161","article-title":"Oncoplastic breast surgery in older women with primary breast cancer: systematic review","volume":"110","author":"Chia","year":"2023","journal-title":"Br J Surg"},{"key":"2025062612014381200_pkaf049-B65","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s10549-024-07566-6","article-title":"Oncologic and cosmetic outcomes of oncoplastic breast-conserving surgery after neoadjuvant systemic therapy: systematic review and meta-analysis","volume":"209","author":"Ahmed","year":"2025","journal-title":"Breast Cancer Res Treat"},{"key":"2025062612014381200_pkaf049-B66","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1093\/bjs\/znac251","article-title":"Immediate breast reconstruction uptake in older women with primary breast cancer: systematic review","volume":"109","author":"Lee","year":"2022","journal-title":"Br J Surg"},{"key":"2025062612014381200_pkaf049-B67","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann Oncol"},{"key":"2025062612014381200_pkaf049-B68","doi-asserted-by":"publisher","first-page":"3261","DOI":"10.1200\/JCO.19.02750","article-title":"Ten-year results of FAST: a\u00a0randomized controlled trial of 5-fraction whole-breast radiotherapy for early breast cancer","volume":"38","author":"Brunt","year":"2020","journal-title":"J Clin Oncol"},{"key":"2025062612014381200_pkaf049-B69","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1016\/S1470-2045(21)00539-8","article-title":"European Society for Radiotherapy and Oncology Advisory Committee in Radiation Oncology Practice consensus recommendations on patient selection and dose and fractionation for external beam radiotherapy in early breast cancer","volume":"23","author":"Meattini","year":"2022","journal-title":"Lancet Oncol"},{"key":"2025062612014381200_pkaf049-B70","doi-asserted-by":"publisher","first-page":"S75","DOI":"10.1016\/S0167-8140(22)02477-X","article-title":"OC-0101 First results of FAST-Forward phase 3 RCT nodal substudy: 3-year normal tissue effects","volume":"170","author":"Wheatley","year":"2022","journal-title":"Radiother Oncol"},{"key":"2025062612014381200_pkaf049-B71","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/S1470-2045(14)71156-8","article-title":"Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial","volume":"16","author":"Bartelink","year":"2015","journal-title":"Lancet Oncol"},{"key":"2025062612014381200_pkaf049-B72","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1200\/JCO.2007.14.5565","article-title":"Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group","volume":"26","author":"Kyndi","year":"2008","journal-title":"J Clin Oncol"},{"key":"2025062612014381200_pkaf049-B73","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1111\/tbj.13193","article-title":"Oncoplastic \u2014breast surgery and radiotherapy\u2014Adverse aesthetic outcomes, proposed classification of aesthetic components, and causality attribution","volume":"25","author":"Agrawal","year":"2019","journal-title":"Breast J"},{"key":"2025062612014381200_pkaf049-B74","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"2025062612014381200_pkaf049-B75","year":"2022"},{"key":"2025062612014381200_pkaf049-B76"}],"container-title":["JNCI Cancer Spectrum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jncics\/advance-article-pdf\/doi\/10.1093\/jncics\/pkaf049\/63199357\/pkaf049.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jncics\/article-pdf\/9\/3\/pkaf049\/63199357\/pkaf049.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jncics\/article-pdf\/9\/3\/pkaf049\/63199357\/pkaf049.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T16:01:48Z","timestamp":1750953708000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jncics\/article\/doi\/10.1093\/jncics\/pkaf049\/8133265"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,30]]},"references-count":76,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,4,30]]}},"URL":"https:\/\/doi.org\/10.1093\/jncics\/pkaf049","relation":{},"ISSN":["2515-5091"],"issn-type":[{"value":"2515-5091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2025,4,30]]},"article-number":"pkaf049"}}